Working… Menu

Efficacy and Safety of PiQo4 Device for Treatment of Melasma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03565341
Recruitment Status : Recruiting
First Posted : June 21, 2018
Last Update Posted : June 18, 2019
Information provided by (Responsible Party):
Focus Medical, LLC

Brief Summary:

Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm & 585nm combination treatment.

Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 months following the last treatment.

Condition or disease Intervention/treatment Phase
Melasma Device: PiQo4 Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Face sides will be randomized to receive either 1064nm alone or 1064nm & 585nm combination treatment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy and Safety of the PiQo4 Picosecond Laser (PSL) System for the Treatment of Patients With Melasma: A Prospective, Randomized, Split Face Study Comparing the Added Value of 585nm Over 1064nm PSL
Actual Study Start Date : July 2, 2018
Estimated Primary Completion Date : July 30, 2019
Estimated Study Completion Date : August 2020

Arm Intervention/treatment
Experimental: Melasma
Treatment of Melasma Using PiQo4 Laser System
Device: PiQo4
PiQo4 Laser System for treatment of Melasma

Primary Outcome Measures :
  1. Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on at least one of the face sides at the 1-month follow-up visit. [ Time Frame: 1 month follow up ]
    The study will be deemed successful if the point estimate of the percent of successful subjects will be at least 50%.

Secondary Outcome Measures :
  1. Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on at least one of the face sides at the 3-month follow-up visit [ Time Frame: 3 months follow up ]
  2. Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on each face side [ Time Frame: 6 months follow up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy Female
  2. Age= 18-75.
  3. Fitzpatrick skin phototype = II-V
  4. Melasma severity: diagnosed with mild to severe melasma lesions (MSS≥2)
  5. Melasma type: Dermal or mixed type melasma, confirmed by Wood's lamp test
  6. Melasma duration: The subject's melasma has persisted for greater than 6 months
  7. Melasma previous treatments: has failed to respond to conventional treatment with hydroquinone or other topical lightening agents
  8. Able to read, understand and provide written Informed Consent.
  9. Able and willing to comply with the treatment/follow-up schedule and post treatment care
  10. Agreed to use the same facial skin care products during the clinical trial period (including the follow-up period)
  11. Agreed to the prohibition of the use of local/systemic corticosteroids or retinoids and other local/systemic lightening medications, and willing to abide by such instructions
  12. Agreed to the daily use of an over SPF 50 sunblock on their face during the clinical trial period (including the follow-up period), and willing to abide by such instructions
  13. Agreed to have their face photographed and willingness to allow Focus Medical (the study Sponsor) and Lumenis and the investigators to use de-identified photographs of the treated area for presentation and publication purposes
  14. (In case of fertile women) Tested negative in the pregnancy test and agreed to use birth control contraceptives during the clinical trial period - Oral contraceptives are forbidden as they may influence the results of the clinical study.
  15. Agreed not to undergo any other procedure on their face during their participation in the clinical trial

Exclusion Criteria:

  1. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 3 months after completion of breastfeeding
  2. Known hypersensitivity or contraindications to anaesthetic agents including lidocaine and its derivatives
  3. Participation in a study of another device or drug within three months prior to enrolment or during the study.
  4. Presence of open wounds or lesions in the area
  5. Extensive scarring or tattoos in areas to be treated.
  6. Having other pigmentation disorder
  7. Having an excessive underlying vascular condition (e.g. dense network of capillaries).
  8. Suffering from current or history of significant skin conditions in the treated area that could interfere with the evaluation (i.e. infection, dermatitis, or rash on their face) or requires the use of interfering topical or systemic therapy.
  9. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
  10. Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen
  11. Subjects who are opposed to possible damage to the hair follicles with possible loss of hair in the treatment area
  12. Laser or medium/deep chemical peel, or surgery, or filler treatments using collagen, hyaluronic acid, or any other material at area of treatment, within 6 months of initial treatment or during the course of the study.
  13. IPL or superficial chemical peel within the previous 1 month
  14. Topical therapy with retinoids, imiquimod, 5-fluorouracil, ingenol mebutate, diclofenac, alpha-hydroxy acids, or salicylic acids within the previous 1 month.
  15. Currently using topical retinoid, hydroquinone or corticosteroid or whitening cream such as alpha arbutin, azelaic acid, kojic acid ascorbic acid or any cosmetics within 2 weeks
  16. Lightening oral medication (hydroquinone, tranexamic acid), isotretinoid (or retinoid), light-sensitive medication, or steroids in the last 6 months
  17. History of keloid scarring, hypertrophic scarring, or of abnormal wound healing.
  18. History of connective tissue diseases such as systemic lupus erythematosus or scleroderma
  19. Active leukoplakia, eczema, or psoriasis in the treatment area
  20. History of post inflammatory pigmentary disorders, particularly a tendency for hyper- or hypo-pigmentation.
  21. History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
  22. Has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present
  23. History of skin cancer in the treatment area
  24. Significant concurrent illness or any disease state that in the opinion of the Investigator would interfere with the treatment or healing process
  25. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
  26. Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician's discretion).
  27. History of hormonal therapy in the last 3 months (e.g., estrogen, progesterone, or oral contraceptive)
  28. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03565341

Layout table for location contacts
Contact: David J Goldberg, MD (201)441-9890
Contact: Diana Aranzazu 201-951-0701

Layout table for location information
United States, New Jersey
Hackensack University Medical Center - Skin Laser & Surgery Specialists Of NY & NJ Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Diana Aranzazu    201-951-0701      
Principal Investigator: David J Goldberg, MD         
Sponsors and Collaborators
Focus Medical, LLC
Layout table for investigator information
Principal Investigator: David J Goldberg, MD Hackensack University Medical Center - Skin Laser & Surgery Specialists Of NY & NJ

Layout table for additonal information
Responsible Party: Focus Medical, LLC Identifier: NCT03565341     History of Changes
Other Study ID Numbers: Focus-PiQo4 Melasma-17-04
First Posted: June 21, 2018    Key Record Dates
Last Update Posted: June 18, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Pigmentation Disorders
Skin Diseases